Elafibranor (2) – Iqirvo®

Primary biliary cholangitis (in combination with ursodeoxycholic acid)

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Elafibranor
Brand name Iqirvo®
Pharm. company Ipsen Pharma GmbH
G-BA Procedure ID D-1398
Therapeutic area n.d. Orphan (turnover limit)
Reason for procedure Reassessment: Orphan turnover exceeded

Associated procedures

Elafibranor (2) Iqirvo® Ipsen Pharma GmbH n.d. Primary biliary cholangitis (in combination with ursodeoxycholic acid) n.d. active procedure Orphan (turnover limit)
Elafibranor (1) Iqirvo® Ipsen Pharma GmbH Digestive system diseases Primary biliary cholangitis (combination with ursodeoxycholic acid) 6,000–13,000 100% Hint for minor additional benefit Orphan


<< List of all resolutions